跳至主要内容
临床试验/NCT07316621
NCT07316621招募中不适用

Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives

GLSMED Learning Health S.A.10 个研究点 分布在 6 个国家目标入组 10,000 人开始时间: 2026年4月1日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
10,000
试验地点
10
主要终点
Development of Crohn's disease during the study period

研究概览

简要总结

The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease.

This study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland.

To achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions.

At the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 35 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female participants, between 16 and 35 years old
  • FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD
  • Participants able to understand the information provided to them and to give written informed assent or consent for the study.

排除标准

  • Prior diagnosis of IBD
  • Any legal or medical condition that limits the information and participation in the study
  • Inability to verify CD diagnosis in the proband
  • Participants unwilling or unable to provide informed written consent
  • Participants unwilling or unable to donate blood for serum

研究组 & 干预措施

First-degree relatives

结局指标

主要结局

Development of Crohn's disease during the study period

时间窗: From enrolment until end of study follow-up (up to 3 years)

Diagnosis confirmed according to established diagnostic criteria, specifically endoscopy and histopathology

Assess the performance of a risk model for at-risk population for CD

时间窗: through study development, an average of 1-3 year

The model will integrate measures of predefined serum biomarkers of at-risk population (first degree relatives of CD patients) with clinical and lifestyle factors. The performance can than be assessed by the risk prediction of participants which are then diagnosed with CD.

次要结局

  • Proportion of first-degree relatives classified as high risk according to the PREDICT-CD risk prediction algorithm(From enrolment until end of study follow-up (up to 3 years))
  • Clinical and lifestyle characteristics of high-risk individuals who develop inflammatory bowel disease(From enrolment until end of study follow-up (up to 3 years))
  • Incidence of newly diagnosed immune-mediated inflammatory diseases other than Crohn's disease(From enrolment until end of study follow-up (up to 3 years))
  • Participant-reported willingness to receive predictive risk information and participate in preventive interventions(From enrolment until end of study follow-up (up to 3 years))
  • Prevalence of risk factors in FDRs developing IBD(throughout the study, in average 1-3 years)

研究者

发起方
GLSMED Learning Health S.A.
申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验